Article
Therapeutic index 'low': AMD treatment feasible, but Santen pulls out
Salt Lake City-IOMED Inc. and Santen Pharmaceuticals Co. said they have ended a joint development agreement intended to launch a noninvasive ophthalmic drug delivery system to provide an anti-angiogenic drug to the retina and choroid in therapeutic quantities.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
